## **AMENDMENTS TO CLAIMS**

This listing of claims will replace all prior version and listings of claims in this application:

## 1. (Previously Presented) A compound of the Formula (i),

Formula (I)

wherein A may be either -CR<sub>11</sub>R<sub>12</sub>-, -C=O or -SO<sub>2</sub>-;

 $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_6$ ,  $R_7$ ,  $R_8$  and  $R_9$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{13}$ ,  $R_{14}$  and  $R_{15}$  may be same or different and each independently represent hydrogen, halogen, oxo, thio, perhaloalkyl, perhaloalkoxy, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>2</sub>-C<sub>12</sub>)alkenyl, (C<sub>2</sub>-C<sub>12</sub>)alkynyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkenyl, bicycloalkyl, bicycloalkenyl, (C<sub>1</sub>-C<sub>12</sub>)alkoxy, cyclo(C<sub>3</sub>-C<sub>7</sub>)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, aryloxycarbonyl, heterocyclylalkoxycarbonyl, aralkoxycarbonyl, heteroaryloxycarbonyl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio. thioalkyl. alkoxycarbonylamino, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino, dialkylaminocarbonylamino. alkylamidino, alkylguanidino. dialkylguanidino. hydrazino. hydroxylamino, carboxylic acid and its derivatives, sulfonic acids and its derivatives, phosphoric acid and its derivatives; or

the adjacent groups like  $R_1$  and  $R_2$  or  $R_2$  and  $R_3$  or  $R_3$  and  $R_4$  or  $R_6$  and  $R_7$  or  $R_7$  and  $R_8$  or  $R_8$  and  $R_9$  together with carbon atoms to which they are attached may form a five or a six membered ring, optionally containing one or more double bonds and optionally containing one

or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; or

optionally  $R_{11}$  and  $R_{12}$  together with the carbon atoms to which they are attached may form a three to six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; or optionally either  $R_{11}$  or  $R_{12}$  with may form bond with either  $R_{16}$  or  $R_{17}$  to form a 5, 6 or 7-membered heterocyclic ring, which may be further substituted with  $R_{14}$  and  $R_{15}$ , and may have either one, two or three double bonds;

 $R_{13}$ ,  $R_{16}$  and  $R_{17}$  may be same or different and each independently represents Hydrogen, substituted or unsubstituted groups selected from linear or branched ( $C_1$ - $C_{12}$ )alkyl, ( $C_2$ - $C_{12}$ )alkenyl, ( $C_2$ - $C_{12}$ )alkynyl, ( $C_3$ - $C_7$ )cycloalkyl, ( $C_3$ - $C_7$ )cycloalkenyl, bicycloalkyl, bicycloalkenyl, aryl, aralkyl, heteroaryl, heterocyclylalkyl; optionally  $R_{13}$  along with either  $R_{16}$  or  $R_{17}$  and the two nitrogen atoms may form a 5, 6 or 7-membered heterocyclic ring, which may be further substituted with  $R_{14}$  and  $R_{16}$ , and may have either one, two or three double bonds; and

"n" is an integer ranging from 1 to 4, wherein the carbon chains which "n" represents may be either linear or branched.

- 2. (Previously Presented) A compound according to Claim-1 which is selected from: 10-(4-Methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-d- ioxide; 1-Bromo-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 1-Chloro-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 2-Bromo-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 2-Bromo-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide hydrochloride salt;
- 2-Methoxy-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide:
- 2-Methoxy-12-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-benzo[4,5]pentaleno[1,2-b]naphthalene-5,5-dioxide;
- 2-Ethoxy-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;

- 2-Ethoxy-8-methyl-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene 5,5-dioxide;
- 2-Benzyloxy-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 2-Cyclopentyloxy-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5.5-dioxide;
- 2-Cyclohexyloxy-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 2-(Furan-2-ylmethoxy)-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 1,2,3-Trichloro-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 2,8-Dimethoxy-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 2-Bromo-8-methoxy-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 8-Methoxy-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 8-Methoxy-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide hydrochloride salt:
- 8-lsopropoxy-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide:
- 2-Bromo-8-methyl-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 4-Methyl-10-(4-methylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]ind- ene-5,5-dioxide:
- (RS) 8-Methyl-10-[1-(4-methylpiperazin-1-yl)ethyl]-5-thia-4b-aza-indeno[2,1-a]- indene-5,5-dioxide;
- (RS) 2-Methoxy-10-[1-(4-methylpiperazin-1-yl)ethyl]-5-thia-4b-aza-indeno[2,1-a-]indene-5,5-dioxide;
- (RS) 2-Bromo-8-methoxy-10-[1-(4-methylpiperazin-1-yl)ethyl]-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- (RS) 1-[4-(8-Methoxy-5,5-dioxo-5H-5□6-thia-4b-aza-indeno[2,1-a]inden-10-ylmethyl)-2-methylpiperazin-1-yl]ethanone;

- 10-(4-Pyridin-2-yl-piperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide; 8-Methoxy-10-(4-pyridin-2-yl-piperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide; 5,5-dioxide;
- 2-Isopropoxy-10-(4-benzoylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 2-(Furan-2-ylmethoxy)-10-(4-benzoylpiperazin-1-ylmethyl)-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 10-(4-Benzylpiperazin-1-ylmethyl)-8-methyl-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 10-(4-Benzylpiperazin-1-ylmethyl)-8-methoxy-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
  - 2-Methoxy-10-piperazin-1-ylmethyl-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
  - 2-lsopropoxy-10-piperazin-1-ylmethyl-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 2-(Furan-2-ylmethoxy)-10-piperazin-1-ylmethyl-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- 10-[1,4]Diazepan-1-ylmethyl-2-methoxy-5-thia-4b-aza-indeno[2,1-a]indene-5- ,5-dioxide; 1-[4-(5,5-Dioxo-5H-5□6-thia-4b-aza-indeno[2,1-a]inden-10-ylmethyl)-[1,4]diazepan-1-yl]phenylmethanone;
- 10-(4-Ethyl-[1,4]diazepan-1-ylmethyl)-2-methoxy-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide; and
- 10-(4-Isopropyl-[1,4]diazepan-1-ylmethyl)-2-methoxy-5-thia-4b-aza-indeno[2,1-a]indene-5,5-dioxide;
- or a stereoisomer, or any suitable combination of above, such as a nitrogen oxide thereof;
- 3. (Previously Presented) A process for the preparation of a compound of Formula (I),

Formula (I)

wherein A may be either -CR<sub>11</sub>R<sub>12</sub>-, -C=O or -SO<sub>2</sub>-;

 $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_6$ , R,  $R_8$  and  $R_9$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{13}$ ,  $R_{14}$  and  $R_{15}$  may be same or different and each independently represent hydrogen, halogen, oxo, thio, perhaloalkyl, perhaloalkoxy, hydroxy, amino, nitro, cyano, formyl, amidino, guanidino, substituted or unsubstituted groups selected from linear or branched  $(C_1-C_{12})$ alkyl,  $(C_2-C_{12})$ alkenyl,  $(C_2-C_{12})$ alkynyl,  $(C_3-C_{12})$  $C_7$ )cycloalkyl,  $(C_3-C_7)$ cycloalkenyl, bicycloalkyl, bicycloalkenyl,  $(C_1-C_{12})$ alkoxy, cyclo $(C_3-C_7)$ cycloalkyl, bicycloalkyl, bicy C<sub>7</sub>)alkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heterocyclylalkyl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, heterocyclylalkyloxy, acyl, acyloxy, acylamino, monoalkylamino, dialkylamino, arylamino, diarylamino, aralkylamino, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, heterocyclylalkoxycarbonyl, heteroaryloxycarbonyl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkoxycarbonylamino, alkylthio, thioalkyl, aryloxycarbonylamino, aralkyloxycarbonylamino, aminocarbonylamino, alkylaminocarbonylamino. dialkylaminocarbonylamino, alkylamidino, alkylguanidino, dialkylguanidino, hvdrazino. hydroxylamino, carboxylic acid and its derivatives, sulfonic acids and its derivatives, phosphoric acid and its derivatives; or

the adjacent groups like  $R_1$  and  $R_2$  or  $R_2$  and  $R_3$  or  $R_3$  and  $R_4$  or  $R_6$  and  $R_7$  or  $R_7$  and  $R_8$  or  $R_8$  and  $R_9$  together with carbon atoms to which they are attached may form a five or a six membered ring, optionally containing one or more double bonds and optionally containing one or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; or

optionally  $R_{11}$  and  $R_{12}$  together with the carbon atoms to which they are attached may form a three to six membered ring, optionally containing one or more double bonds and

optionally containing one or more heteroatoms selected from "Oxygen", "Nitrogen", "Sulfur" or "Selenium" and combinations of double bond and heteroatoms; or

optionally either  $R_{11}$  or  $R_{12}$  with may form bond with either  $R_{16}$  or  $R_{17}$  to form a 5, 6 or 7-membered heterocyclic ring, which may be further substituted with  $R_{14}$  and  $R_{15}$ , and may have either one, two or three double bonds;

 $R_{13}$ ,  $R_{16}$  and  $R_{17}$  may be same or different and each independently represents Hydrogen, substituted or unsubstituted groups selected from linear or branched ( $C_1$ - $C_{12}$ )alkyl, ( $C_2$ - $C_{12}$ )alkenyl, ( $C_3$ - $C_7$ )cycloalkyl, ( $C_3$ - $C_7$ )cycloalkenyl, bicycloalkyl, bicycloalkenyl, aryl, aralkyl, heteroaryl, heterocyclylalkyl;

optionally  $R_{13}$  along with either  $R_{16}$  or  $R_{17}$  and the two nitrogen atoms may form a 5, 6 or 7-membered heterocyclic ring, which may be further substituted with  $R_{14}$  and  $R_{15}$ , and may have either one, two or three double bonds; and

"n" is an integer ranging from 1 to 4, wherein the carbon chains which "n" represents may be either linear or branched; which comprises reacting a compound of formula (II) given below.

Formula (II)

wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_6$ ,  $R_7$ ,  $R_8$ ,  $R_9$ ,  $R_{13}$ ,  $R_{14}$ ,  $R_{15}$ ,  $R_{16}$ ,  $R_{17}$ , A and n are as defined previously, or precursor thereof, while either  $R_5$  or  $R_{10}$  is a halogen atom such as bromo, chloro or iodo, and the other is hydrogen; with a Pd(0) or Pd (II) derivative as a catalyst.

- 4. (Cancelled)
- 5. (Cancelled)
- 6. (Cancelled)

- 7. (Curerntly Amended) A pharmaceutical composition comprising either of a pharmaceutically acceptable carrier, diluent, <u>or excipients or solvate along</u> with a therapeutically effective amount of a compound according to Claim-1, its stereoisomers, its radioisotopes, its Novides, and any suitable combination of the above.
- 8. (Original) A pharmaceutical composition according to Claim-3, in the form of a tablet, capsule, powder, syrup, injectable, solution or suspension.
  - 9. (Cancelled)
  - 10. (Cancelled)
  - 11. (Cancelled)
  - 12. (Cancelled)
  - 13. (Cancelled)
  - 14. (Cancelled)
  - 15. (Cancelled)
  - 16. (Cancelled)
  - 17. (Cancelled)